NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/robert-langreth-fiona-rutherford-immanual-john-milton
Sign In To follow
The recommendation is a huge win for the pharmaceutical company, likely paving the way for the company's first-of-its-kind gene therapy for treat Duchenne muscular dystrophy, a deadly disease.